Evidence · Randomised trial
Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial.
- Medical
- Respiratory
- Respiratory distress syndrome and surfactant
This paper is from 2017, more than five years ago. Newer evidence may have been published since.
Summary
Multicentre randomised placebo-controlled trial (PROGRESS) assessing whether vaginal progesterone pessaries in women with a previous spontaneous preterm birth reduce the risk and severity of neonatal respiratory distress syndrome. Around 790 infants were analysed, with no difference in RDS incidence, severity of respiratory disease, serious infant composite outcomes or preterm birth rates between groups. Maternal morbidities and treatment side effects were similar. The authors conclude the results do not support routine use of vaginal progesterone for this purpose, suggesting individual participant data meta-analysis may identify subgroups who benefit.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.